Last reviewed · How we verify
ENMETAZOBACTAM
ENMETAZOBACTAM is a drug. It is currently FDA-approved (first approved 2024).
At a glance
| Generic name | ENMETAZOBACTAM |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 2024 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate PK, Safety, Tolerability of Cefepime-enmetazobactam in Pediatric Participants With cUTI (PHASE2)
- Pharmacokinetics of Cefepime and AAI101 in Subjects With Renal Insufficiency and Healthy Subjects (PHASE1)
- Lung Pharmacokinetics (PK) in Epithelial Lining Fluid (ELF) (PHASE1)
- Single Dose Mass Balance Study With C14 - Labeled AAI101 in Healthy Male Volunteers (PHASE1)
- Investigation of AAI101 Safety, Tolerability & PK in Healthy Volunteers (PHASE1)
- Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ENMETAZOBACTAM CI brief — competitive landscape report
- ENMETAZOBACTAM updates RSS · CI watch RSS
Frequently asked questions about ENMETAZOBACTAM
What is ENMETAZOBACTAM?
ENMETAZOBACTAM is a Small molecule drug.
When was ENMETAZOBACTAM approved?
ENMETAZOBACTAM was first approved on 2024.
What development phase is ENMETAZOBACTAM in?
ENMETAZOBACTAM is FDA-approved (marketed).
Related
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing